Merck
CN
All Photos(1)

Documents

260266

Sigma-Aldrich

1,2-Epoxytetradecane

technical grade, 85%

Sign Into View Organizational & Contract Pricing
All Photos(1)
Empirical Formula (Hill Notation):
C14H28O
CAS Number:
3234-28-4
Molecular Weight:
212.37
EC Number:
221-781-6
MDL number:
MFCD00037524
PubChem Substance ID:
24855729
NACRES:
NA.23

grade

technical grade

Assay

85%

form

liquid

refractive index

n20/D 1.4408 (lit.)

bp

95-96 °C/0.4 mmHg (lit.)

density

0.845 g/mL at 25 °C (lit.)

SMILES string

CCCCCCCCCCCCC1CO1

InChI

1S/C14H28O/c1-2-3-4-5-6-7-8-9-10-11-12-14-13-15-14/h14H,2-13H2,1H3

InChI key

IOHJQSFEAYDZGF-UHFFFAOYSA-N

Related Categories

Pictograms

Exclamation markEnvironment
GHS07,GHS09

Signal Word

Warning

Hazard Statements

H315 - H410

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Skin Irrit. 2

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Flash Point(C)

105 °C - closed cup

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Ping Song et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 27(8), 1424-1435 (2019-06-04)
Interleukin-1 beta (IL-1β) plays a central role in the induction of rheumatoid arthritis (RA). In the present study, we demonstrated that lipidoid-polymer hybrid nanoparticle (FS14-NP) can efficiently deliver siRNA against IL-1β (siIL-1β) to macrophages and effectively suppress the pathogenesis of
Eva Ramsay et al.
Pharmaceutics, 12(7) (2020-07-28)
Inflammation is involved in the pathogenesis of several age-related ocular diseases, such as macular degeneration (AMD), diabetic retinopathy, and glaucoma. The delivery of anti-inflammatory siRNA to the retinal pigment epithelium (RPE) may become a promising therapeutic option for the treatment
Shantipriya Khadka et al.
Electrophoresis, 37(23-24), 3160-3171 (2016-09-10)
A novel precursor monolithic capillary column referred to as "hydroxy monolith" or OHM was prepared by the in situ copolymerization of hydroxyethylmethacrylate (HEMA) with pentaerythritol triacrylate (PETA) yielding the neutral poly(HEMA-co-PETA) monolith. The neutral precursor OHM capillary thus obtained was
Wei Tao et al.
Science translational medicine, 12(553) (2020-07-29)
Atherosclerotic lesional macrophages express molecules that promote plaque progression, but lack of mechanisms to therapeutically target these molecules represents a major gap in translational cardiovascular research. Here, we tested the efficacy of a small interfering RNA (siRNA) nanoparticle (NP) platform
Rachel S Riley et al.
Science advances, 7(3) (2021-02-02)
Clinical advances enable the prenatal diagnosis of genetic diseases that are candidates for gene and enzyme therapies such as messenger RNA (mRNA)-mediated protein replacement. Prenatal mRNA therapies can treat disease before the onset of irreversible pathology with high therapeutic efficacy

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service